US EditionUS expected roll out new COVID-19 booster vaccines in September as 'Eris' variant rises
- A new COVID-19 booster vaccine, targeting the XBB.1.5 variant, is expected to be available in the US in September as hospitalizations rise from the EG.5 "Eris" variant, a descendant of the XBB lineage.
- Demand for the vaccine has dropped sharply since 2021, and health experts anticipate that the booster shots may be met with skepticism and declining concern about the virus, posing challenges for the vaccination campaign.
- The US approach to vaccination will shift from government-bought supplies to making the booster shots available in the commercial market.
11 Articles
11 Articles
New Covid Vaccines Are on the Way as ‘Eris’ Variant Rises
NEW YORK, Aug 14 (Reuters) - A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from "Eris", a variant of the Omicron form of the coronavirus, rise around the country.
US expected roll out new COVID-19 booster vaccines in September as 'Eris' variant rises
NEW YORK: A new COVID-19 booster vaccine is expected to be available in the United States in September as hospitalisations in the country rise from the EG.5 "Eris" variant, a descendant of the XBB lineage.
New Covid vaccines are on the way as 'Eris' variant rises
A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from "Eris", a variant of the Omicron form of the coronavirus, rise around the country. Some public health experts hope that Americans will welcome the new shot as they would a flu jab. But demand for the vaccine has dropped sharply since 2021 when it first became available and more than 240 million people in…
Coverage Details
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
